Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith

1. A method for the treatment of Duchenne Muscular Dystrophy in a human patient with a nonsense mutation at one or more positions in the dystrophin gene; comprising administering to the patient having Duchenne Muscular Dystrophy and a nonsense mutation at one or more positions in the dystrophin gene, an effective amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid

or a pharmaceutically acceptable salt thereof,

in three doses, wherein the three doses comprise a first dose, a second dose and a third dose, and wherein the amounts of the first dose and the second dose are the same and the amount of the third dose is twice the amount of the first dose, in a plurality of 24 hour time periods, wherein the second dose is administered about 6 hours after the first dose is administered, the third dose is administered about 6 hours after the second dose is administered, and the first dose for a next 24 hour time period is administered about 12 hours after the third dose was administered for a preceding 24 hour time period, and wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in a range of about 2 μg/mL to about 20 μg/mL is maintained in said patient for a 24 hour time period;

wherein said patient has been determined to have a likelihood of responding to treatment through a pre-treatment patient screening, said patient screening comprising contacting a cell sample from said patient in vitro with 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid

or a pharmaceutically acceptable salt thereof, and measuring the expression or activity of dystrophin protein produced in the presence of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof compared to the absence of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof, wherein increased expression or activity of functional readthrough dystrophin protein in said contacted cell sample relative to a cell sample from said patient not contacted with 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof indicates a likelihood that said patient will respond to treatment, wherein said cell sample is a muscle tissue sample from a patient undergoing pre-treatment screening or said cell sample is a dermal fibroblast sample from a patient undergoing pre-treatment screening, wherein the dermal fibroblasts have been differentiated into muscle cells in vitro by transfection with a Myo-D-producing expression construct.

2. The method of claim 1 , wherein the cell sample is a muscle tissue sample from a patient undergoing pre-treatment screening.

3. The method of claim 1 , wherein the cell sample is a dermal fibroblast sample from a patient undergoing pre-treatment screening, wherein the dermal fibroblasts have been differentiated into muscle cells in vitro by transfection with a Myo-D-producing expression construct.

4. The method of claim 1 , wherein the nonsense mutation at one or more positions in the dystrophin gene is found at least at positions selected from 1417, 3625 or 492 of the dystrophin gene.

5. The method of claim 4 , wherein the cell sample is a muscle tissue sample from a patient undergoing pre-treatment screening.

6. The method of claim 4 , wherein the cell sample is a dermal fibroblast sample from a patient undergoing pre-treatment screening, wherein the dermal fibroblasts have been differentiated into muscle cells in vitro by transfection with a Myo-D-producing expression construct.